We agree on the possible causes of such a low frequency of HBV screening in addition to the lack of physicians’ education and compliance. We do believe that HBV screening and eventually vaccination in RA patients before starting a bDMARD therapy is a hot issue which requires more attention by the rheumatology scientific societies in order to widely spread the message and improve the adherence of rheumatologists to the recommendations from both the EULAR and the ACR (3, 4).

P. Meroni1
D. Zavaglia2
C. Girmenia3
1 Immunorheumatology Research Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy;
2 Medical Department, Pfizer Italia, Rome, Italy;
3 Department of Haematology, Oncology and Dermatology, Azienda Policlinico Umberto I, Sapienza University, Rome, Italy.

Please address correspondence to:
Dr Pierluigi Meroni,
Immunorheumatology Research Laboratory,
IRCCS Istituto Auxologico Italiano,
via Zucchi 18, 20095 Cesano Milano, Italy.
E-mail: pierluigi.meroni@unimi.it

Competing interests: none declared.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2018.

References